Athena Athena

X

Find Radio Compass News for Levosimendan

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275

PRESS RELEASE
29 Feb 2024

https://www.globenewswire.com//news-release/2024/02/20/2831850/0/en/Tenax-Therapeutics-Announces-Global-License-Amendment-that-Significantly-Expands-Rights-to-Levosimendan.html

GLOBENEWSWIRE
20 Feb 2024

https://www.globenewswire.com//news-release/2024/02/08/2825648/0/en/Tenax-Therapeutics-Enrolls-First-Patient-in-Phase-3-LEVEL-Study-Evaluating-TNX-103-Oral-Levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-in-Heart-Failure-with-Preserved-Eje.html

GLOBENEWSWIRE
07 Feb 2024

https://www.globenewswire.com//news-release/2023/11/13/2779076/0/en/Tenax-Therapeutics-Announces-FDA-Clearance-of-IND-for-TNX-103-oral-levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-H.html

GLOBENEWSWIRE
13 Nov 2023

https://www.globenewswire.com/news-release/2023/07/19/2707305/0/en/Tenax-Therapeutics-Issued-U-S-Patent-for-Oral-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html

GLOBENEWSWIRE
19 Jul 2023

https://www.globenewswire.com/news-release/2023/02/01/2600032/0/en/Tenax-Granted-Notice-of-Allowance-for-U-S-Patent-Application-Covering-Use-of-IV-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-and-Preserved-Ejection-Fraction-PH-HFpEF.html

GLOBENEWSWIRE
01 Feb 2023

https://www.globenewswire.com/news-release/2022/10/10/2531000/0/en/Positive-Data-Presented-at-HFSA-Annual-Meeting-Demonstrate-Effects-of-Oral-Levosimendan-in-Patients-with-Pulmonary-Hypertension-and-Heart-Failure-with-Preserved-Ejection-Fraction-P.html

GLOBENEWSWIRE
10 Oct 2022

https://www.globenewswire.com/news-release/2022/01/12/2365672/0/en/Tenax-Therapeutics-Granted-U-S-Patent-for-the-Subcutaneous-Use-of-Levosimendan-TNX-102.html

GLOBENEWSWIRE
12 Jan 2022

https://www.businesswire.com/news/home/20210812005089/en

BUSINESSWIRE
12 Aug 2021

https://www.businesswire.com/news/home/20201015005109/en

BUSINESSWIRE
15 Oct 2020

https://www.biospace.com/article/releases/tenax-therapeutics-gains-north-american-rights-to-oral-levosimendan-through-expanded-license-agreement-with-orion-corporation/#:~:text=(Nasdaq%3A%20TENX)%2C%20a,develop%20and%20commercialize%20in%20the

BIOSPACE
15 Oct 2020

https://www.globenewswire.com/news-release/2020/07/28/2068949/0/en/Orion-s-phase-3-REFALS-trial-evaluating-the-efficacy-of-oral-levosimendan-in-treatment-of-ALS-patients-did-not-reach-its-pre-specified-endpoints.html

GLOBENEWSWIRE
28 Jul 2020

https://www.businesswire.com/news/home/20200602005359/en

BUSINESSWIRE
02 Jun 2020

https://www.businesswire.com/news/home/20200409005099/en

BUSIBNESSWIRE
09 Apr 2020

https://www.businesswire.com/news/home/20200113005041/en

BUSINESSWIRE
13 Jan 2020

https://www.businesswire.com/news/home/20191031005067/en

BUSINESSWIRE
31 Oct 2019

https://www.businesswire.com/news/home/20190311005094/en/Tenax-Therapeutics-Enrolls-Patient-Phase-2-Pulmonary/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

BUSINESSWIRE
11 Mar 2019

https://www.fiercebiotech.com/research/newly-discovered-als-mechanism-could-open-up-for-drug-development

Angus Liu FIERCE BIOTECH
06 Sep 2018

https://www.fiercebiotech.com/orion-take-repurposed-heart-failure-drug-into-phase-3-for-als

Phil Taylor FIERCE BIOTECH
06 Jul 2018

https://www.businesswire.com/news/home/20180601005198/en

BUSINESSWIRE
01 Jun 2018

https://www.businesswire.com/news/home/20180301005168/en/Tenax-Therapeutics-Announces-New-Scientific-Publication-Preclinical

BUSINESSWIRE
01 Mar 2018
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY